AusperBio
Develops oligonucleotide therapeutics targeting chronic hepatitis B
$120MSeries C
Role not disclosedLoading investors…
Loading investors…
Activity from announced rounds
Develops oligonucleotide therapeutics targeting chronic hepatitis B
Develops in vivo CAR-T cell therapies for cancer and autoimmune diseases
Develops interventional therapies for pulmonary hypertension and heart failure
Develops extrahepatic RNA-targeting therapeutics
Develops next-generation cell therapies for oncology and immunology
Develops intelligent platform-driven macrocyclic peptide drug discovery
Develops minimally invasive implantable brain-machine interfaces (BMI) for neurological diseases
Develops multimodal foundation models for video generation and AI productivity
Develops next-generation cell therapies for oncology and immunology